trending Market Intelligence /marketintelligence/en/news-insights/trending/sWoE-I88d4VsSCXEbi-lYw2 content esgSubNav
In This List

PharmaMar lung cancer drug reduces tumor size in phase 1/2 study

Video

According to Market Intelligence, December 2022

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022


PharmaMar lung cancer drug reduces tumor size in phase 1/2 study

Pharma Mar SA said a combination of Zepsyre and chemotherapy reduced the tumor size of patients with relapsed small cell lung cancer in a phase 1/2 trial.

The Zepsyre phase 1/2 trials, conducted in 27 patients, showed that a combination of the drug and doxorubicin is better than topotecan alone. The combination had a progression-free survival of 5.3 months compared to topotecan's historical data of 3.1 to 3.5 months progression-free survival.

Further, the combination also demonstrated a 37% objective response rate versus the topotecan rates of between 17% and 24%.

The results of the trial were presented by PharmaMar at the International Association for the Study of Lung Cancer's World Conference on Lung Cancer held in Japan.